Ibuprofen
- Half-Life (t½)
- PO: 1.9h · IV: 1.9h
- Formula
- C13H18O2
- Molecular Weight
- 206.28 g/mol
- Aliases
- Advil, Motrin, Brufen
Pharmacological Mechanism
Reversible non-selective arachidonic acid cascade COX inhibitor. Reduces prostaglandin synthesis → analgesia, anti-inflammation, antipyresis. Reversibility means antiplatelet effect is dose-dependent + reversible (unlike aspirin's irreversible acetylation).
Half-Life & Elimination Curve (PO: 1.9h · IV: 1.9h)
Plasma (PO)t½ Decay (1.9h)Effect Site (ke0)
- 0×t½0h100% (23.3 mg/L)
- 1×t½1.9h50% (11.6 mg/L)
- 2×t½3.8h25% (5.82 mg/L)
- 3×t½5.7h12.5% (2.91 mg/L)
- 4×t½7.6h6.3% (1.45 mg/L)
- 5×t½9.5h3.1% (0.727 mg/L)
Dosing Guidelines
- Oral (PO): Typical 400 mg (Range: 200–800 mg)
- Intravenous (IV): Typical 400 mg (Range: 200–800 mg)
- Transdermal (TD): Typical 400 mg (Range: 200–800 mg)
Pharmacokinetic Parameters
- Oral (PO): Bioavailability (F): 85% · Volume of Distribution (Vd): 10 L · Absorption (ka): 2 h⁻¹ (t½ka ≈ 21m) [PMID 28856569]
- Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 10 L [PMID 28856569]
- Effect-Site Equilibration (ke0): 0.667 h⁻¹ (equilibration half-time t½ke0 ≈ 1.04h) [PMID 30117229]
Receptor Binding & Occupancy
Pathways It Modulates
Target Organ Systems
Interactions
- Acetaminophen (synergistic): Complementary mechanisms — APAP + ibuprofen outperforms either alone for post-op/dental pain.
- Apixaban (caution): Additive GI bleed risk; avoid chronic co-use. [Holbrook 2005]
- Aspirin (caution): Ibuprofen may block aspirin's COX-1 acetylation site if taken within 2 h prior — reduces cardioprotective effect.
- Dabigatran (caution): Additive GI bleeding; avoid chronic combination. [Holbrook 2005]
- Rivaroxaban (caution): Additive GI bleed risk; avoid chronic co-use. [Holbrook 2005]
- Warfarin (caution): Plasma protein-binding displacement at HSA. Chan 1989 (PMID:2724076) equilibrium dialysis: free warfarin 5–9% with ibuprofen vs 2.5–6% baseline. Low-end Δfu = (5 − 4.25)/4.25 ≈ 0.18. In-vitro magnitude; clinical effect smaller. Dominant clinical concern is COX-1/platelet additive bleed risk + GI mucosal injury, not displacement.
Chemical Structure & Identifiers
- InChIKey: HEFNNWSXXWATRW-UHFFFAOYSA-N
- SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
References